Diagnosticos Da America S.a.BMFBOVESPA: DASA3

Dasa posted double-digit EBITDA growth and closed its transformative joint venture with Amil

· Issued by Diagnosticos Da America S.a.

Dasa delivered strong 1Q25 results with 11% EBITDA growth, margin expansion, and reduced net loss, while closing a major joint venture with Amil and maintaining disciplined capital allocation. Leverage and liquidity remain stable, supporting long-term value creation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Diagnosticos Da America

All Diagnosticos Da America news releases